
STRO Stock Forecast & Price Target
STRO Analyst Ratings
Bulls say
Sutro Biopharma Inc. is demonstrating promising advancements in its clinical development pipeline, particularly with STRO-004 showing enhanced safety and efficacy through its innovative design, leading to improved anti-tumor activity in multiple cancer models. The company is strategically restructuring to optimize capital allocation, which includes a notable workforce reduction projected to decrease operating expenses by 50-70% starting in 2Q25, thereby enhancing financial sustainability through 2026. Additionally, the introduction of STRO-006, with its selective antibody design aimed at integrating β6 ADC, positions Sutro with competitive advantages in a rapidly evolving biopharmaceutical landscape.
Bears say
Sutro Biopharma's financial outlook has deteriorated significantly due to several critical factors, including a projected net loss of $227.4 million for FY24, alongside a decrease in cash reserves from $388.3 million to $316.9 million, which could limit further development activities. The company faces substantial risks regarding clinical results for its lead antibody-drug conjugate (ADC) candidates, which, if underperforming, could lead to downward adjustments in market penetration and timelines for approval, further impacting the share price negatively. Additionally, the recent decision to reduce workforce by nearly 50% and discontinue the luvelta program, once central to its valuation, signal a strategic pivot that could hinder growth prospects and investor confidence.
This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
STRO Analyst Forecast & Price Prediction
Start investing in STRO
Order type
Buy in
Order amount
Est. shares
0 shares